Gavin Herbert Eye Institute 17th Annual Colloquium

October 20 - 21, 2023

Purpose

Gavin Herbert Eye Institute's 17th Annual Colloquium - "Updates and Concepts in Ophthalmology" - is designed to improve the participant's competence, knowledge, and skills, and should improve their performance within their practice through the use new skills and strategies. The format is a combination of didactic lectures utilizing both PowerPoint and surgical videos to illustrate new techniques and technologies and will present complication management and avoidance to comprehensive ophthalmologists. In addition, panel and audience discussions will be used to encourage interactive learning with attendees and faculty.

Target Audience

This activity was developed for ophthalmologists, ophthalmology researchers, and other ophthalmology healthcare professionals.

Activity Objectives

At the conclusion of this activity, the participants should be able to:

- 1. Learn the indications for when drops, lasers, minimally invasive approaches or tubes / trabeculectomies are indicated in glaucoma patients.
- 2. Conduct an evaluation of pre- and post-operative refractive error and evaluate appropriate treatment options.
- 3. Understand the advances in diagnostic criteria, monitoring ability, and disease etiology that have occurred in the last few years in neuro-ophthalmology that will improve our ability to take care of patients.
- 4. Evaluate the treatment options available for treating progressive myopia in young patients.
- 5. Highlight the advantages and limitations of using AI and ChatGPT in clinical practice and medical education.
- 6. Decide between currently available AMD and DM treatments.
- 7. How oculoplastic procedures positively and negatively affect ocular surface disease.
- 8. Understand a stepwise approach to diagnose uveitis, starting with the identification of key clinical features and then selecting appropriate investigations based on the suspected underlying cause.

Accreditation Statement

The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The University of California, Irvine School of Medicine designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credits $^{\text{TM}}$. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

California Assembly Bill 1195 and 241

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, https://medschool.uci.edu/cme for AB 1195 and AB 241 resources.

Faculty List

Nisha Acharya, MD; Professor, UCSF Department of Ophthalmology
Soroosh Behshad, MD; Associate Clinical Professor, UCI Department of Ophthalmology
Andrew Browne, MD, PhD; Assistant Clinical Professor, UCI Department of Ophthalmology
Robert Crow, MD; Associate Clinical Professor, UCI Department of Ophthalmology
Maria Del Valle Estopinal; Assistant Clinical Professor, UCI Department of Ophthalmology
Lilangi Ediriwickrema, MD; Assistant Clinical Professor, UCI Department of Ophthalmology
Marjan Farid, MD; Clinical Professor, UCI Department of Ophthalmology
Austin Fox, MD; Assistant Clinical Professor, UCI Department of Ophthalmology
Sumit (Sam) Garg, MD; Clinical Professor, UCI Department of Ophthalmology

Charlotte Gore, MD; Assistant Clinical Professor, UCI Department of Ophthalmology Sanjay Kedhar, MD; Clinical Professor, UCI Department of Ophthalmology Baruch D. Kuppermann, MD, PhD; Professor and Chair, UCI Department of Ophthalmology Olivia Lee, MD; Associate Clinical Professor, UCI Department of Ophthalmology Ken Lin, MD, PhD; Associate Clinical Professor, UCI Department of Ophthalmology Stephanie Lu, MD; Associate Clinical Professor, UCI Department of Ophthalmology Mitul Mehta, MD; Associate Clinical Professor, UCI Department of Ophthalmology Kapil Mishra, MD; Assistant Clinical Professor, UCI Department of Ophthalmology Sameh Mosaed, MD; Clinical Professor, UCI Department of Ophthalmology Vivek Patel, MD; Clinical Professor, UCI Department of Ophthalmology Mohammad Riazi Esfahani, MD; Clinical Professor, UCI Department of Ophthalmology Thomas Samuelson, MD; Minnesota Eye Consultants Andrew Smith, MD; Assistant Clinical Professor, UCI Department of Ophthalmology Samuel Spiegel, MD; Assistant Clinical Professor, UCI Department of Ophthalmology Donny Suh, MD; Clinical Professor, UCI Department of Ophthalmology Jeremiah Tao, MD; Clinical Professor, UCI Department of Ophthalmology Matthew Wade, MD; Associate Clinical Professor, UCI Department of Ophthalmology

Agenda

| Agenda | | |
|-------------------|--|---------------------------------------|
| | | |
| | 17 th Annual Gavin Herbert Eye Institute Colloquium | |
| | Arnold and Mabel Beckman Center | |
| | October 20-21, 2023 | |
| | · · | |
| | Friday, October 20, 2023 | SPEAKER |
| 44.00 4.00 004 | | 1-11-78: |
| 12:00 - 1:00 PM | Registration / Lunch | Lobby / Dining Room |
| 1:00 PM - 1:10 AM | Welcome | Baruch D. Kuppermann, MD, PhD |
| 1:10 - 2:30 PM | RETINA SESSION | Moderator: Barry Kuppermann, MD, PhD |
| 2120 21301111 | Panel discussion: -The Retina Specialist's Octopus's Garden | moderator. Sarry Roppermann, Mo, 1 no |
| | Panel: Andrew Browne, MD, PhD; Barry Kuppermann, MD, PhD; Stephanie Lu, MD; | |
| | Mitul Mehta, MD; Mohammad Riazi, MD | |
| | Case: In the shade: DME Update | |
| | Case: Near a cave: Injections and treatments for dry AMD | |
| | Case: On the seabed: Wet AMD algorithm | |
| | Q&A | |
| | | |
| | Small chorodial melanomas: diagnosos and treatment | Kapil Mishra, MD |
| | Q&A | |
| | | |
| 2:30 - 3:00 PM | Afternoon Break with Exhibitors | Atrium |
| | | |
| 3:00 - 5:00 PM | REFRACTIVE (LENS/CORNEA) AND GLAUCOMA SESSION | Moderator: Sam Garg, MD |
| 3:00 - 5:00 PM | Latest in presbyopia management: IOLs and drops | Matthew Wade, MD |
| | Next generation corneal refractive surgery | Soroosh Beshad, MD |
| | Panel discussion: Light My Fire: IOL choices and calculations in abnormal eyes | Moderator: Sam Garg, MD |
| | Panel: Austin Fox, MD; Sam Garg, MD; Sanjay Kedhar, MD; Ken Lin, MD, PhD; | |
| | Sameh Mosaed, MD; Thomas Samuelson, MD; Andrew Smith, MD; Matthew Wade, MD | |
| | Q&A | |
| | | |
| | Steinert Memorial Lecture: Interventional glaucoma: rationale and execution | Thomas Samuelson, MD |
| | Q&A | |
| | MIGS Skills Trasfer Wetlab - introduction | Complete Manager MR |
| | Saturday: AM group will start at 7:30 am PM group will start at 12:30 PM | Sameh Mosaed, MD |
| | Saturday. Am group will start at 7.50 am Fin group will start at 12.50 FM | |
| 5:00 - 6:00 PM | Reception | Atrium |
| SIGO - GIGO FIN | MIGS Skills Transfer Wetlab - signup | Autum |
| | THE STATE OF THE S | |
| | | |

| | Saturday, October 21, 2023 | SPEAKER |
|---------------------|--|-------------------------------|
| | | |
| :00 - 8:30 AM | Registration Breakfast | Lobby and Dining Room |
| | | |
| :30 - 8:30 AM | MIGS SKILLS TRANSFER WETLAB SESSION #1 | Newport Room |
| | * Registration is limited * Pre-register at the front desk * | |
| | Instructors: | |
| | Austin Fox, MD; Sam Garg, MD; Ken Lin, MD, PhD; Sameh Mosaed, MD; Andrew Smith, MD | |
| :30 - 9:30 AM | CATARACT SESSION | Moderator: Matthew Wade, MD |
| | Panel discussion: In Your Eyes - EDOF or not? | Panel |
| | Case: Day pass: glaucoma / ON issues | Thomas Samuelson, MD |
| | Case: Without a noise: eEpiretinal membrane | Miitul Mehta, MD |
| | Case: The grand façade: difficult patient | Sam Garg, MD |
| | Case: All my instincts: pseudoexfoliation | Austin Fox, MD |
| | Case: get so lost : kerataconus | Soroosh Beshad, MD |
| | Case: The resolution : endothelial disease | Sanjay Kedhar, MD |
| | Case: The light, the heat: uveitis | Nisha Acharya, MD |
| | | |
| :30 - 10:00 AM | Morning Break with Exhibitors | |
| 10:00 AM - 11:00 AM | PLASTICS SESSION | Moderator: Jeremiah Tao, MD |
| | Panel discussion: We Didn't Start the Fire: orbital disasters: what's hot and what's not | |
| | Panel: Lilangi Ediriwickrema, MD; Maria Del Valle Estopinal, MD; Jeremiah Tao, MD | |
| | Case: Marilyn Monroe: orbital cellulitis | |
| | Case: Joe DiMaggio: orbital fractures | |
| | Case: Kerouac : thyroid eye disease | |
| | Q&A | |
| 4.00.40.00.00 | APPLIATED OFFICIAL | |
| 1:00 - 12:00 PM | PEDIATRIC SESSION | Moderator: Charlotte Gore, MD |
| | Coat of Many Colors | Charlesta Cara MD |
| | PEDIG randomized control myopia trial outcomes | Charlotte Gore, MD |
| | Myopia research at Gavin Herbert Eye Institute | Stephen Prepas, MD |
| | Pediatric uveitis | Wendy Huang, MD |
| | Adalimumab in juvenile idiopathic arthritis-associated uveitis | Nisha Acharya, MD |
| | Q&A | |
| 2.00 1.20 054 | Lunch Naturation Eulikitary | Dining Boom |
| 2:00- 1:30 PM | Lunch Networking Exhibitors | Dining Room |

| MIGS SKILLS TR | Sa | meh Mosaed, MD |
|------------------|-----------|------------------------------|
| * Registration L | | |
| Instructors: | Ne | ewport Room |
| Austin Fox, N | | |
| UVEITIS SESSIOI | Me | oderator: Sanjay Kedhar, MD |
| Scleritis: medic | Oli | livia Lee, MD |
| Molecular path | Sa | anjay Kedhar, MD |
| Gavin Herbert I | Ni | isha Acharya, MC |
| Q&A | | |
| Panel discussio | M | loderator: Sanjay Kedhar, MD |
| Panel: Olivia | MD | |
| Case: V | | |
| Case: P | | |
| Case: T | | |
| Case: T | | |
| Afternoon Brea | At | trium |
| NEURO-OPHTHA | Me | oderator: Vivek Patel, MD |
| Panel discussio | | |
| Panel: Wade | atel, MD | |
| Case: In | | |
| Case: De | | |
| Case: Do | | |
| Q&A | | |
| CORNEA SESSIO | Mo | oderator: Olivia Lee, MD |
| Clarity | | |
| Endothelial cel | Sa | anjay Kedhar, MD |
| Ocular surface | <u>Sa</u> | am Garg, MD |
| Neurotrophic k | OI | livia Lee, MD |
| Q&A | | |
| Closing Remark | Ma | atthew Wade, MD |
| Closing Remark | | <u>M</u> |

Acknowledgement of Ineligible Company Support

The University of California, Irvine Gavin Herbert Eye Institute thank the following companies for their financial support of this educational activity:

Grant | Sponsor Support

Coherus; Dompe; Genentech; Johnson & Johnson; Justin Wine; Regeneron; SightSciences; STAAR; Zeiss

Exhibitors

Alcon; Allergan, an AbbVie Company; Apellis; Bausch & Lomb; Coherus; CorneaGen; Dompe; Genentech, Glaukos; Iveric Bio; Johnson & Johnson; New World Medical; RxSight; Tarsus; Thea Pharma

Gavin Herbert Eye Institute 17th Annual Colloquium

October 20 - 21, 2023

UCI OCME requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. Planning must be free of the influence or control of an ineligible company (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients), and promote improvements or quality in healthcare. It is the policy of the UCI Office of Continuing Medical Education to insure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty and planners participating in UCI accredited CME programs are required to disclose to the activity participants any real or apparent conflict(s) of interest. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations that may be considered ineligible companies. The intent of this policy is identifying potential conflicts of interest so participants can form their own judgments with full disclosure of the facts. It remains for the participants to determine whether the speaker's outside interests reflect a possible bias in either the exposition or the conclusions presented.

This activity's director(s), speakers, planners, peer reviewer, authors, coordinators and moderators have no financial relationships to disclose, except the following:

| | Name of Ineligible Company | Nature of Relevant Relationship | Conflict Mitigation Method |
|----------------------------------|---|--|--|
| Nisha Acharya, MD | Abbvie | Grants / Research Support | Peer reviewed. Speaker will state their conflicts. |
| Nisha Acharya, MD | Roche | Advisor or Review Panel Member | Peer reviewed. Speaker will state their conflicts. |
| Marjan Farid, MD | Allergan; Bausch + Lomb; Bio-Tissue, Inc.; CorneaGen; Dompe; Johnson & Johnson Vision, KALA, Novartis; Orasis; Sun Pharmaceutical; Tarsus; Zeiss | Advisor or Review Panel Member, Consultant | Peer reviewed. Speaker will state their conflicts. |
| Sumit Garg, MD | Allergan; Glaukos; Johnson & Johnson Vision; Tarsus; Visus; | Consultant | Peer reviewed. Speaker will state their conflicts. |
| Sanjay Kedhar, MD | Visus Therapeutics | Consultant | Peer reviewed. Speaker will state their conflicts. |
| Baruch Kuppermann, MD, PhD | EyeBio; Eyedaptic; Glaukos; Interface Biologics; jCyte; ReVana Therapeutics; Ripple Therapeutics; Theravance Biopharma | Consultant | Peer reviewed. Speaker will state their conflicts. As planner, they recused themselves and deferred to Dr. Garg in the planning of any activity content related to their disclosure information. |

| Baruch Kuppermann, MD, PhD | Allergan | Grants/Research Support, Consultant, Speakers' Bureau | Peer reviewed. Speaker will state their conflicts. As planner, they recused themselves and deferred to Dr. Garg in the planning of any activity content related to their disclosure information. |
|----------------------------------|---|--|--|
| Baruch Kuppermann, MD, PhD | Genentech, Inc. | Grants/Research Support; Consultant | Peer reviewed. Speaker will state their conflicts. As planner, they recused themselves and deferred to Dr. Garg in the planning of any activity content related to their disclosure information. |
| Baruch Kuppermann, MD, PhD | Ioni | Grants/Research Support | Peer reviewed. Speaker will state their conflicts. As planner, they recused themselves and deferred to Dr. Garg in the planning of any activity content related to their disclosure information. |
| Baruch Kuppermann, MD, PhD | Allegro Ophthalmics; IVERIC Bio; Novartis Pharmaceuticals; Regeneron Pharmaceuticals; | Grants/Research Support; Consultant | Peer reviewed. Speaker will state their conflicts. As planner, they recused themselves and deferred to Dr. Garg in the planning of any activity content related to their disclosure information. |
| Olivia Lee, MD | Cloudbreak Therapeutics | Consultant | Peer reviewed. Speaker will state their conflicts. |
| Ken Lin, MD, PhD | Aerie Pharmaceuticals | Speakers' Bureau | Peer reviewed. Speaker will state their conflicts. |

| Ken Lin, MD, PHD | Zeiss | Grants/Research | Peer reviewed. |
|-------------------------|---|------------------|-------------------------------------|
| | | | Speaker will state their conflicts. |
| Mitul Mehta, MD | Allergan | Consultant, | Peer reviewed. |
| | | Speakers' Bureau | Speaker will state their |
| | | | conflicts. |
| Mitul Mehta, MD | Eyedaptic | Employee | Peer reviewed. |
| | | | Speaker will state their |
| | | | conflicts. |
| Mitul Mehta, MD | Apellis; DORC | Speakers' Bureau | Peer reviewed. |
| | | | Speaker will state their |
| Mital Malata MD | Alimana | Osnaviltant | conflicts. |
| Mitul Mehta, MD | Alimera | Consultant | Peer reviewed. |
| | | | Speaker will state their conflicts. |
| Sameh Mosaed, | Aerie Pharmaceuticals; | Speakers' Bureau | Peer reviewed. |
| MD | Bausch + Lomb | Speakers Dureau | Speaker will state their |
| | Badder 1 Lorris | | conflicts. |
| Vivek Patel, MD | Horizon Therapeutics | Consultant | Peer reviewed. |
| | | | Speaker will state their |
| | | | conflicts. |
| Kapil Mishra, MD | Bausch & Lomb | Consultant | Peer reviewed. |
| | | | Speaker will state their |
| | | | conflicts. |
| Kapil Mishra, MD | RegenxBio | Consultant | Peer reviewed. |
| | | | Speaker will state their |
| | | | conflicts. |
| Mohammad Riazi, | Aerie Pharmaceuticals; | Consultant | Peer reviewed. |
| MD | Alcon Surgical; Allergan | | Speaker will state their |
| Mohammad Diazi | Polonos (Equinov): Polkin | Conquitant | conflicts. |
| Mohammad Riazi, MD | Balance (Equinox); Belkin Vision; Elios; Ivantis; | Consultant | Peer reviewed. |
| | Ocuphire; SightScience; | | Speaker will state their conflicts. |
| | Tear Clear; Vialase | | connicts. |
| Thomas | Aerie Pharmaceuticals; | Consultant | Peer reviewed. |
| Samuelson, MD | Alcon Surgical; Allergan; | | Speaker will state their |
| | Avellino Labs; Balance | | conflicts. |
| | (Equinox); Bausch + | | |
| | Lomb/Valeant BELKIN | | |
| | Vision; Elios (previously ELT Sight); Equinox | | |
| | Expert Opinion; Glaukos; | | |
| | Imprimis; Irisvision; | | |
| | Ivantis; Johnson & | | |
| | Johnson Vision; | | |
| | MicroOptx; New World | | |
| | Medical; Ocuphire; | | |
| | PolyActiva; Ripple; Therapeutics; Santen; | | |
| | Sight Science; TearClear; | | |
| | Vialase; Zeiss Meditec | | |

| Thomas Samuelson, MD | Balance (Equinox); Belkin Vision; Elios; Equinox; Ivantis; Ocuphire; Sight Science; Tear Clear; Vialase | Stock Shareholder (excluding mutual funds) | Peer reviewed. Speaker will state their conflicts. |
|-------------------------|---|--|--|
| Matthew Wade, MD | Johnson & Johnson Vision; Glaukos; Tarsus | Consultant | Peer reviewed. Speaker will state their conflicts. |

| All conflicts have been mitigated in advance. | | | |
|---|---|--|--|
| | | | |
| | - | | |

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, Irvine School of Medicine.

All content in this activity: Copyright ©2023 The Regents of the University of California. All rights reserved.